MedTrace Logo

Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

NCT06610890 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-12-03

No results posted yet for this study

Summary

1. To evaluate the pharmacokinetics of Hemay005 tablets on midazolam and its active metabolite α-hydroxymidazolam after multiple administration;
2. Evaluate the effect of Hemay005 tablet on QT interval;
3. To investigate the effect of Hemay 005 tablets on inflammatory factors.

Conditions

Interventions

DRUG

Hemay005

One 15mg tablet, four tablets at a time

DRUG

Midazolam maleate

One 15mg tablet, one tablet at a time

Sponsors & Collaborators

  • Ganzhou Hemay Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-12
Primary Completion
2025-01-20
Completion
2025-01-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06610890 on ClinicalTrials.gov